High frequencies of KMT2C and KMT2D mutations also downregulate ERα and FOXA1 expression, suggesting that the loss of KMT2C/D can reduce the sensitivity of luminal breast cancer to ER inhibitors by activating the hormone-independent pathway [163]. This evidence concerns the gene ESR1 and breast carcinoma.